Basic information
- Name:
Fenofibric acid
- CAS No.:
42017-89-0
- Molecular Structure:

- Formula:
- C17H15ClO4
- Molecular Weight:
- 318.75
- Synonyms:
- 2-[4'-(p-Chlorobenzoyl)phenoxy]-2-methylpropionic acid;2-[p-(p-Chlorobenzoyl)phenoxy]-2-methylpropionic acid;FNF acid;LF 153;LF 178 acid;NSC 281318;Procetofenic acid;a-1081;2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid;Propanoic acid,2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-;
- EINECS:
- 255-626-9
- Density:
- 1.287 g/cm3
- Melting Point:
- 177-179 °C
- Boiling Point:
- 486.457 °C at 760 mmHg
- Flash Point:
- 248.001 °C
- Appearance:
- white to off-white solid
- Risk Codes:
- 36/37/38
- Safety Description:
- 26-36/37/39 Details
Famous Chemical Enterprises
-
Livzon -
Total -
Shell -
Dupont -
Exxonmobil -
Akzonobel -
Basf -
Bayer -
BP
Please post your buying leads,so that our qualified suppliers will soon
contact you!
*Required Fields
History
Consensus Reports
Fenofibric acid increased transcription of ABCA1 gene in a liver X receptor–dependent manner. Fibrates are widely used drugs to reduce plasma triglyceride and increase high-density lipoprotein. Their active forms, fibric acids, are peroxisome proliferator-activated receptor- activators, but no direct evidence has been demonstrated for their activation of ATP-binding cassette transporter A1 (ABCA1) in relation to clinically used fibrates. We investigated the reaction of fenofibric acid in this regard, finding that fenofibric acid increased transcription of ABCA1 gene in n liver X receptor–dependent manner.
Analytical Methods
Specification
The Fenofibric acid, with the CAS registry number 42017-89-0, is also known as 2-[4'-(p-Chlorobenzoyl)phenoxy]-2-methylpropionic acid. It belongs to the product categories of Pharmacetical; Various Metabolites and Impurities; Intermediates & Fine Chemicals; Metabolites & Impurities; Pharmaceuticals; Aromatics. Its EINECS number is 255-626-9. This chemical's molecular formula is C17H15ClO4 and molecular weight is 318.75. What's more, its systematic name is 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid. Its classification codes are: (1)Anticholesteremic Agents; (2)Antilipemic agents; (3)Antimetabolites; (4)Drug / Therapeutic Agent. This chemical is used as pharmaceutical intermediates and intermediate of fenofibrate. It is the active metabolite of fenofibrate.
Physical properties of Fenofibric acid are: (1)ACD/LogP: 3.992; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 1.60; (4)ACD/LogD (pH 7.4): 0.35; (5)ACD/BCF (pH 5.5): 2.55; (6)ACD/BCF (pH 7.4): 1.00; (7)ACD/KOC (pH 5.5): 14.17; (8)ACD/KOC (pH 7.4): 1.00; (9)#H bond acceptors: 4; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 5; (12)Polar Surface Area: 63.6 Å2; (13)Index of Refraction: 1.585; (14)Molar Refractivity: 83.048 cm3; (15)Molar Volume: 247.696 cm3; (16)Polarizability: 32.923×10-24cm3; (17)Surface Tension: 49.10 dyne/cm; (18)Density: 1.287 g/cm3; (19)Flash Point: 248.001 °C; (20)Enthalpy of Vaporization: 79.223 kJ/mol; (21)Boiling Point: 486.457 °C at 760 mmHg; (22)Vapour Pressure: 0 mmHg at 25°C.
When you are using this chemical, please be cautious about it as the following:
This chemical is irritating to eyes, respiratory system and skin. In case of contact with eyes, you should rinse immediately with plenty of water and seek medical advice. When using it, you need to wear suitable protective clothing, gloves and eye/face protection.
You can still convert the following datas into molecular structure:
(1)SMILES: O=C(c1ccc(Cl)cc1)c2ccc(OC(C(=O)O)(C)C)cc2
(2)Std. InChI: InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)
(3)Std. InChIKey: MQOBSOSZFYZQOK-UHFFFAOYSA-N
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | intraperitoneal | 500mg/kg (500mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 26, Pg. 885, 1976. | |
| mouse | LD50 | oral | 1200mg/kg (1200mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 26, Pg. 885, 1976. | |
| rat | LD50 | intravenous | 313mg/kg (313mg/kg) | LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 23. |
| rat | LD50 | oral | 1242mg/kg (1242mg/kg) | Drugs of the Future. Vol. 7, Pg. 229, 1982. |

